Login to Your Account



Clinic Roundup


Monday, May 6, 2013

• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., completed patient enrollment in the company's final pivotal U.S. Phase III NX02-0018 study of NX-1207 for benign prostatic hyperplasia (BPH). Top-line results are expected in early 2014.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription